RNS Number : 2588F
Deepverge PLC
03 November 2022
 

 

3 November 2022

 

DeepVerge PLC

 

("DeepVerge" or "Company")

 

Board Changes

DeepVerge (AIM: DVRG), the environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins, confirms that, further to the notifications made on 25 October 2022, 27 October 2022 and 1 November 2022,  the following Board changes have taken place:

Gerard Brandon has stepped down as Chief Executive, and remains on the board as Executive Director with responsibility for the Modern Water Division.

Dr Nigel Burton is interim Chief Executive while the Company commences the search for a new Group Chief Executive.

Fionan Murray remains on the Board as Executive Director with responsibility for the Skin Trust Club and Labskin Division.

Camillus Glover has left the board, however remains as Chief Financial Officer while the Company commences the search for a new Group Finance Director.

For further information, please contact:

Enquiries:

 

DeepVerge plc

Nigel Burton, Interim Chief Executive

+44 7785 234447

 




SPARK Advisory Partners Limited

(Nominated Adviser)

Neil Baldwin

+44 (0) 113 370 8974




Turner Pope Investments (TPI) Limited

(Broker)

Andy Thacker/James Pope

+44 (0) 20 3657 0050

 

 

Market Abuse Regulation (MAR) Disclosure

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAUOOURURUARAA